Markets:

Overview

News

Currencies

International

Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

6.285 -0.095 (-1.49%)

Streaming Delayed Price Updated: 2:47 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

May 05, 2025

Via Benzinga

BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased ↗

May 05, 2025

BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.

Via Stocktwits

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 05, 2025

Via Benzinga

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today ↗

February 24, 2025

Via The Motley Fool

A Preview Of BioCryst Pharma's Earnings ↗

February 23, 2024

Via Benzinga

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript ↗

February 24, 2025

BCRX earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings ↗

February 24, 2025

BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.

Via Benzinga

Earnings Scheduled For February 24, 2025 ↗

February 24, 2025

Via Benzinga

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript ↗

November 04, 2024

BCRX earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 04, 2024

Via Benzinga

Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

August 06, 2024

EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END

Via FinancialNewsMedia

Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

August 06, 2024

From FN Media Group LLC

Via GlobeNewswire

BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript ↗

August 05, 2024

BCRX earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

7 Small-Cap Stocks to Buy for Large-Scale Gains ↗

July 30, 2024

Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.

Via InvestorPlace

3 Insider-Buy Stocks to Add to Your Watchlist Now

July 09, 2024

Insiders are buying these stocks that should be on your radar, but only two are set up to rebound and move higher today; the third may move lower first.

Via MarketBeat

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 15, 2024

Via Benzinga

NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday ↗

May 15, 2024

Via Benzinga

Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday ↗

May 06, 2024

A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally.

Via The Motley Fool

BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance ↗

May 06, 2024

BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic...

Via Benzinga

BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript ↗

May 06, 2024

BCRX earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session ↗

May 06, 2024

Via Benzinga

BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024 ↗

May 06, 2024

BCRX stock results show that BioCryst Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects ↗

March 01, 2024

These penny stocks offer triple digit returns to investors right now but not many investors are aware of them.

Via InvestorPlace

BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript ↗

February 26, 2024

BCRX earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

What's Going On With BioCryst Stock After Earnings? ↗

February 26, 2024

BioCryst reported quarterly losses of 28 cents per share, missing the analyst consensus estimate of losses of 24 cents by 16.67% and representing a 26.32% increase over losses of 38 cents per share...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 26, 2024

Via Benzinga

Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

February 26, 2024

U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday.

Via Benzinga

Topics Stocks

Earnings Scheduled For February 26, 2024 ↗

February 26, 2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.

Via Benzinga

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 08, 2024

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today